BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges

No Timetable in Sight

 
• By Brian Yang
  
CHINA ZERO COVID DETERS FDA INSPECTIONS TO THE COUNTRY
BEIGENE/NOVARTIS PD-1 AGENT FACES FDA APPROVAL DELAY DUE TO CHINA'S 'COVID ZERO' POLICIES • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership